Relationship of Lupus Anticoagulant, Anticardiolipin, Anti-β₂-GPI and Anti-prothrombin Autoantibodies with History of Thrombosis in Patients with the Clinical Suspicion of APA-Syndrome

• References

• 1 Horbach DA, van OortE, Donders RCJM, Derksen RHWM, de GrootPG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-924
• 2 Triplett DA, Bama LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993; 70: 787-793
• 3 Sletnes KE, Gravem K, Wisloff F. Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies. Thromb Res 1992; 66: 43-53
• 4 Amiral J, Larrivaz I, Cluzeau D, Adam M. Standardization of immunoassays for antiphospholipid antibodies withβ₂GPI and role of their phospholipid cofactors. Haemostasis 1994; 24: 191-203
• 5 Fermo I, Vigano’D’Angelo S, Paroni R, Mazzola G, Calori G, D’Angelo A. Prevalence of moderate hyperhomocyst(e)inemia in patients with early- onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753
• 6 Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691
• 7 Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995; 99: 624-628